help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KANEHIRO, A.
Right arrow Articles by GELFAND, E. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KANEHIRO, A.
Right arrow Articles by GELFAND, E. W.

Am. J. Respir. Crit. Care Med., Volume 162, Number 3, September 2000, 1132-1139

Timing of Administration of Anti-VLA-4 Differentiates Airway Hyperresponsiveness in the Central and Peripheral Airways in Mice

ARIHIKO KANEHIRO, KATSUYUKI TAKEDA, ANTHONY JOETHAM, ADRIAN TOMKINSON, TOSHIHIDE IKEMURA, CHARLES G. IRVIN, and ERWIN W. GELFAND

Division of Basic Sciences, Department of Pediatrics and Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado

The development of airway hyperresponsiveness (AHR) is correlated with the infiltration into the lungs of activated eosinophils and T lymphocytes. In large part, influx of eosinophils into the lung is dependent on very late activating antigen-4 (VLA-4) expression. However, the kinetics of eosinophil recruitment and the development of AHR are not fully delineated. Airway function was monitored by changes in lung resistance (RL) and dynamic compliance (Cdyn) to methacholine (MCh) inhalation after anti-VLA-4. After ovalbumin (OVA) sensitization and airway challenge of BALB/c mice, AHR increased as did the number of lung inflammatory cells. Administration of anti-VLA-4 to sensitized mice 2 h before the first (of three) OVA airway challenges significantly prevented changes in RL. Moreover, injection of the antibody from 2 h before the first challenge to 42 h after the last challenge significantly prevented the increases in RL, as well as eosinophil and lymphocyte numbers in the bronchoalveolar lavage fluid (BALF); interleukin-5 (IL-5) and leukotriene concentrations in BALF were also significantly inhibited. Interestingly, treatment with anti-VLA-4 only prevented changes in Cdyn and goblet cell hyperplasia when administered 2 h before the first challenge. These studies demonstrate that the timing of anti-VLA-4 administration can selectively affect pathologic processes that contribute to altered airway function in the central and peripheral airways after allergen challenge.




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
S. R. Barthel, M. W. Johansson, D. M. McNamee, and D. F. Mosher
Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma
J. Leukoc. Biol., January 1, 2008; 83(1): 1 - 12.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
A. Hirano, A. Kanehiro, K. Ono, W. Ito, A. Yoshida, C. Okada, H. Nakashima, Y. Tanimoto, M. Kataoka, E. W. Gelfand, et al.
Pirfenidone Modulates Airway Responsiveness, Inflammation, and Remodeling after Repeated Challenge
Am. J. Respir. Cell Mol. Biol., September 1, 2006; 35(3): 366 - 377.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
T. Koya, T. Kodama, K. Takeda, N. Miyahara, E.-S. Yang, C. Taube, A. Joetham, J.-W. Park, A. Dakhama, and E. W. Gelfand
Importance of Myeloid Dendritic Cells in Persistent Airway Disease after Repeated Allergen Exposure
Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 42 - 55.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. M. Hartney, K. G. Coggins, S. L. Tilley, L. A. Jania, A. K. Lovgren, L. P. Audoly, and B. H. Koller
Prostaglandin E2 protects lower airways against bronchoconstriction
Am J Physiol Lung Cell Mol Physiol, January 1, 2006; 290(1): L105 - L113.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
W. Ito, A. Kanehiro, K. Matsumoto, A. Hirano, K. Ono, H. Maruyama, M. Kataoka, T. Nakamura, E. W. Gelfand, and M. Tanimoto
Hepatocyte Growth Factor Attenuates Airway Hyperresponsiveness, Inflammation, and Remodeling
Am. J. Respir. Cell Mol. Biol., April 1, 2005; 32(4): 268 - 280.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
K. Takeshita, T. Yamasaki, S. Akira, F. Gantner, and K. B. Bacon
Essential role of MHC II-independent CD4+ T cells, IL-4 and STAT6 in contact hypersensitivity induced by fluorescein isothiocyanate in the mouse
Int. Immunol., May 1, 2004; 16(5): 685 - 695.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Taube, C. Duez, Z.-H. Cui, K. Takeda, Y.-H. Rha, J.-W. Park, A. Balhorn, D. D. Donaldson, A. Dakhama, and E. W. Gelfand
The Role of IL-13 in Established Allergic Airway Disease
J. Immunol., December 1, 2002; 169(11): 6482 - 6489.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Kanehiro, M. Lahn, M. J. Makela, A. Dakhama, A. Joetham, Y.-H. Rha, W. Born, and E. W. Gelfand
Requirement for the p75 TNF-{alpha} Receptor 2 in the Regulation of Airway Hyperresponsiveness by {gamma}{delta} T Cells
J. Immunol., October 15, 2002; 169(8): 4190 - 4197.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. Kudlacz, C. Whitney, C. Andresen, A. Duplantier, G. Beckius, L. Chupak, A. Klein, K. Kraus, and A. Milici
Pulmonary Eosinophilia in a Murine Model of Allergic Inflammation Is Attenuated by Small Molecule alpha 4beta 1 Antagonists
J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 747 - 752.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. Dakhama, A. Kanehiro, M. J. Makela, J. E. Loader, G. L. Larsen, and E. W. Gelfand
Regulation of Airway Hyperresponsiveness by Calcitonin Gene-related Peptide in Allergen Sensitized and Challenged Mice
Am. J. Respir. Crit. Care Med., April 15, 2002; 165(8): 1137 - 1144.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. KANEHIRO, T. IKEMURA, M. J. MÄKELÄ, M. LAHN, A. JOETHAM, A. DAKHAMA, and E. W. GELFAND
Inhibition of Phosphodiesterase 4 Attenuates Airway Hyperresponsiveness and Airway Inflammation in a Model of Secondary Allergen Challenge
Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 173 - 184.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society